Targeting antigens to dendritic cells in vivo

Immunobiology

Volumn 211, Issue 6-8, 2006, Pages 599-608

  Tacken, Paul J ^a   Torensma, Ruurd ^a   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenovirus; Antigen; Cross presentation; Dendritic cell; Liposome; Targeting

Indexed keywords

ANTIGEN; BETA2 INTEGRIN; CD209 ANTIGEN; CD40 ANTIGEN; CELL SURFACE RECEPTOR; DENDRITIC CELL VACCINE; FC RECEPTOR; GLYCOSPHINGOLIPID; LECTIN RECEPTOR; LIGAND; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNAN; MANNOSE RECEPTOR; MUCIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PEPTIDE; POLYMER; VIRUS VECTOR;

ADVANCED CANCER; ANTIGEN PRESENTATION; BREAST CARCINOMA; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNOREGULATION; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA; REVIEW; STOMACH CARCINOMA; T LYMPHOCYTE; VACCINATION;

EID: 33747362405     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2006.05.021     Document Type: Review

References (87)

1. Apostolopoulos V., Pietersz G.A., Loveland B.E., Sandrin M.S., and McKenzie I.F. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. USA 92 (1995) 10128-10132
2. Apostolopoulos V., Pietersz G.A., Gordon S., Martinez-Pomares L., and McKenzie I.F. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur. J. Immunol. 30 (2000) 1714-1723
3. Arigita C., Bevaart L., Everse L.A., Koning G.A., Hennink W.E., Crommelin D.J.A., van de Winkel J.G.J., van Vugt M.J., Kersten G.F.A., and Jiskoot W. Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response. Infect. Immun. 71 (2003) 5210-5218
4. Arnaout M.A. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75 (1990) 1037-1050
5. Bell D., Young J.W., and Banchereau J. Dendritic cells. Adv. Immunol. 72 (1999) 255-324
6. Belousova N., Korokhov N., Krendelshchikova V., Simonenko V., Mikheeva G., Triozzi P.L., Aldrich W.A., Banerjee P.T., Gillies S.D., Curiel D.T., and Krasnykh V. Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol. 77 (2003) 11367-11377
7. Berry J.D., Licea A., Popkov M., Cortez X., Fuller R., Elia M., Kerwin L., Kubitz D., and Barbas III C.F. Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybrid. Hybridomics 22 (2003) 23-31
8. Binder R.J., and Srivastava P.K. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 6 (2005) 593-599
9. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., and Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196 (2002) 1627-1638
10. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., Brimnes M.K., Moltedo B., Moran T.M., and Steinman R.M. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199 (2004) 815-824
11. Brandao J.G., Scheper R.J., Lougheed S.M., Curiel D.T., Tillman B.W., Gerritsen W.R., van den Eertwegh A.J., Pinedo H.M., Haisma H.J., and de Gruijl T.D. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 21 (2003) 2268-2272
12. Carbone F.R., and Bevan M.J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171 (1990) 377-387
13. Chieppa M., Bianchi G., Doni A., Del Prete A., Sironi M., Laskarin G., Monti P., Piemonti L., Biondi A., Mantovani A., Introna M., and Allavena P. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J. Immunol. 171 (2003) 4552-4560
14. Daeron M. Fc receptor biology. Annu. Rev. Immunol. 15 (1997) 203-234
15. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., Croockewit S., Britten C.M., Torensma R., Adema G.J., Figdor C.G., and Punt C.J. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9 (2003) 5091-5100
16. Delneste Y., Magistrelli G., Gauchat J., Haeuw J., Aubry J., Nakamura K., Kawakami-Honda N., Goetsch L., Sawamura T., Bonnefoy J., and Jeannin P. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17 (2002) 353-362
17. Deo Y.M., Graziano R.F., Repp R., and van de Winkel J.G.J. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol. Today 18 (1997) 127-135
18. Engering A., Geijtenbeek T.B.H., van Vliet S.J., Wijers M., van Liempt E., Demaurex N., Lanzavecchia A., Fransen J., Figdor C.G., Piguet V., and van Kooyk Y. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168 (2002) 2118-2126
19. Fayolle C., Sebo P., Ladant D., Ullmann A., and Leclerc C. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J. Immunol. 156 (1996) 4697-4706
20. Fayolle C., Osickova A., Osicka R., Henry T., Rojas M.J., Saron M.F., Sebo P., and Leclerc C. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J. Virol. 75 (2001) 7330-7338
21. Figdor C.G., van Kooyk Y., and Adema G.J. C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2 (2002) 77-84
22. Frison N., Taylor M.E., Soilleux E., Bousser M.T., Mayer R., Monsigny M., Drickamer K., and Roche A.C. Oligolysine-based oligosaccharide clusters: selective recognition and endocytosis by the mannose receptor and dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin. J. Biol. Chem. 278 (2003) 23922-23929
23. Fukasawa M., Shimizu Y., Shikata K., Nakata M., Sakakibara R., Yamamoto N., Hatanaka M., and Mizuochi T. Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett. 441 (1998) 353-356
24. Geijtenbeek T.B.H., Torensma R., van Vliet S.J., van Duijnhoven G.C.F., Adema G.J., van Kooyk Y., and Figdor C.G. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100 (2000) 575-585
25. Geijtenbeek T.B.H., Groot P.C., Nolte M.A., van Vliet S.J., Gangaram-Panday S.T., van Duijnhoven G.C.F., Kraal G., van Oosterhout A.J.M., and van Kooyk Y. Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens in vivo. Blood 100 (2002) 2908-2916
26. Gieseler R.K., Marquitan G., Hahn M.J., Perdon L.A., Driessen W.H., Sullivan S.M., and Scolaro M.J. DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease. Scand. J. Immunol. 59 (2004) 415-424
27. Gosselin E.J., Wardwell K., Gosselin D.R., Alter N., Fisher J.L., and Guyre P.M. Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens. J. Immunol. 149 (1992) 3477-3481
28. Gramberg T., Caminschi I., Wegele A., Hofmann H., and Pohlmann S. Evidence that multiple defects in murine DC-SIGN inhibit a functional interaction with pathogens. Virology 345 (2006) 482-491
29. Grousson J., and Peguet-Navarro J. Functional relevance of CD40 expression in human epidermis. Cell. Biol. Toxicol. 14 (1998) 345-350
30. Guermonprez P., Ladant D., Karimova G., Ullmann A., and Leclerc C. Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway. J. Immunol. 162 (1999) 1910-1916
31. Guermonprez P., Khelef N., Blouin E., Rieu P., Ricciardi-Castagnoli P., Guiso N., Ladant D., and Leclerc C. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the αMβ2 integrin (CD11b/CD18). J. Exp. Med. 193 (2001) 1035-1044
32. Guo M., Gong S., Maric S., Misulovin Z., Pack M., Mahnke K., Nussenzweig M.C., and Steinman R.M. A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum. Immunol. 61 (2000) 729-738
33. Haicheur N., Bismuth E., Bosset S., Adotevi O., Warnier G., Lacabanne V., Regnault A., Desaymard C., Amigorena S., Ricciardi-Castagnoli P., Goud B., Fridman W.H., Johannes L., and Tartour E. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. 165 (2000) 3301-3308
34. Hattori Y., Kawakami S., Suzuki S., Yamashita F., and Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem. Biophys. Res. Commun. 317 (2004) 992-999
35. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M., and Nussenzweig M.C. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194 (2001) 769-779
36. He L.Z., Ramakrishna V., Connolly J.E., Wang X.T., Smith P.A., Jones C.L., Valkova-Valchanova M., Arunakumari A., Treml J.F., Goldstein J., Wallace P.K., Keler T., and Endres M.J. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin b. Clin. Cancer Res. 10 (2004) 1920-1927
37. Hedley S.J., Auf der Maur A., Hohn S., Escher D., Barberis A., Glasgow J.N., Douglas J.T., Korokhov N., and Curiel D.T. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther. 13 (2006) 88-94
38. Heijnen I.A.F.M., Vugt M.J., Fanger N.A., Graziano R.F., Wit T.P.M., Hofhuis F.M.A., Guyre P.M., Capel P.J.A., Verbeek J.S., and Winkel J.G.J. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97 (1996) 331-338
39. Honeychurch J., Tutt A.L., Valerius T., Heijnen I.A.F.M., van de Winkel J.G.J., and Glennie M.J. Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 96 (2000) 3544-3552
40. Hudson P.J., and Souriau C. Engineered antibodies. Nat. Med. 9 (2003) 129-134
41. Jacewicz M.S., Acheson D.W., Mobassaleh M., Donohue-Rolfe A., Balasubramanian K.A., and Keusch G.T. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J. Clin. Invest. 96 (1995) 1328-1335
42. Kalergis A.M., and Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J. Exp. Med. 195 (2002) 1653-1659
43. Karanikas V., Hwang L.A., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H., Xing P.X., Jamieson G., Pietersz G., Tait B., Broadbent R., Thynne G., and McKenzie I.F. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100 (1997) 2783-2792
44. Keizer G.D., Borst J., Visser W., Schwarting R., De Vries J.E., and Figdor C.G. Membrane glycoprotein p150,95 of human cytotoxic T cell clone is involved in conjugate formation with target cells. J. Immunol. 138 (1987) 3130-3136
45. Keler T., Guyre P.M., Vitale L.A., Sundarapandiyan K., van de Winkel J.G.J., Deo Y.M., and Graziano R.F. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J. Immunol. 165 (2000) 6738-6742
46. Keler T., Ramakrishna V., and Fanger M.W. Mannose receptor-targeted vaccines. Expert. Opin. Biol. Ther. 4 (2004) 1953-1962
47. Kishimoto T.K., Larson R.S., Corbi A.L., Dustin M.L., Staunton D.E., and Springer T.A. The leukocyte integrins. Adv. Immunol. 46 (1989) 149-182
48. Kiyokawa N., Taguchi T., Mori T., Uchida H., Sato N., Takeda T., and Fujimoto J. Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J. Infect. Dis. 178 (1998) 178-184
49. Korokhov N., de Gruijl T.D., Aldrich W.A., Triozzi P.L., Banerjee P.T., Gillies S.D., Curiel T.J., Douglas J.T., Scheper R.J., and Curiel D.T. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol. Ther. 4 (2005)
50. Korokhov N., Noureddini S.C., Curiel D.T., Santegoets S.J., Scheper R.J., and de Gruijl T.D. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol. Pharm. 2 (2005) 218-223
51. LaCasse E.C., Saleh M.T., Patterson B., Minden M.D., and Gariepy J. Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood 88 (1996) 1561-1567
52. Ladant D., and Ullmann A. Bordatella pertussis adenylate cyclase: a toxin with multiple talents. Trends Microbiol. 7 (1999) 172-176
53. Larson R.S., and Springer T.A. Structure and function of leukocyte integrins. Immunol. Rev. 114 (1990) 181-217
54. Lee R.S., Tartour E., van der B.P., Vantomme V., Joyeux I., Goud B., Fridman W.H., and Johannes L. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur. J. Immunol. 28 (1998) 2726-2737
55. Lindberg A.A., Brown J.E., Stromberg N., Westling-Ryd M., Schultz J.E., and Karlsson K.A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem. 262 (1987) 1779-1785
56. Lisziewicz J., Trocio J., Whitman L., Varga G., Xu J., Bakare N., Erbacher P., Fox C., Woodward R., Markham P., Arya S., Behr J.P., and Lori F. DermaVir: a novel topical vaccine for HIV/AIDS. J. Invest. Dermatol. 124 (2005) 160-169
57. Mahnke K., Qian Y., Fondel S., Brueck J., Becker C., and Enk A.H. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res. 65 (2005) 7007-7012
58. Mayadas T.N., and Cullere X. Neutrophil β2 integrins: moderators of life or death decisions. Trends Immunol. 26 (2005) 388-395
59. Moriwaki H., Kume N., Sawamura T., Aoyama T., Hoshikawa H., Ochi H., Nishi E., Masaki T., and Kita T. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1541-1547
60. Moron G., Dadaglio G., and Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 25 (2004) 92-97
61. Nigou J., Zelle-Rieser C., Gilleron M., Thurnher M., and Puzo G. Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J. Immunol. 166 (2001) 7477-7485
62. Ortiz-Stern A., and Rosales C. Cross-talk between Fc receptors and integrins. Immunol. Lett. 90 (2003) 137-143
63. Park C.G., Takahara K., Umemoto E., Yashima Y., Matsubara K., Matsuda Y., Clausen B.E., Inaba K., and Steinman R.M. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int. Immunol. 13 (2001) 1283-1290
64. Pasquier B., Launay P., Kanamaru Y., Moura I.C., Pfirsch S., Ruffie C., Henin D., Benhamou M., Pretolani M., Blank U., and Monteiro R.C. Identification of FcαRI as an inhibitory receptor that controls inflammation: dual role of FcγR ITAM. Immunity 22 (2005) 31-42
65. Postigo A.A., Corbi A.L., Sanchez-Madrid F., and de Landazuri M.O. Regulated expression and function of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and triggering of proliferation through CD11c/CD18. J. Exp. Med. 174 (1991) 1313-1322
66. Ramakrishna V., Treml J.F., Vitale L., Connolly J.E., O'Neill T., Smith P.A., Jones C.L., He L.Z., Goldstein J., Wallace P.K., Keler T., and Endres M.J. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. 172 (2004) 2845-2852
67. Rayevskaya M.V., and Frankel F.R. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J. Virol. 75 (2001) 2786-2791
68. Regnault A., Lankar D., Lacabanne V., Rodriguez A., Thery C., Rescigno M., Saito T., Verbeek S., Bonnerot C., Ricciardi-Castagnoli P., and Amigorena S. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189 (1999) 371-380
69. Reis e Sousa C., and Germain R.N. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182 (1995) 841-851
70. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., Montefiori D., Roberts A., Buonocore L., and Rose J.K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 (2001) 539-549
71. Saron M.F., Fayolle C., Sebo P., Ladant D., Ullmann A., and Leclerc C. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. USA 94 (1997) 3314-3319
72. Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Aiba Y., Tanaka T., Miwa S., Katsura Y., Kita T., and Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature 386 (1997) 73-77
73. Schlecht G., Loucka J., Najar H., Sebo P., and Leclerc C. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming. J. Immunol. 173 (2004) 6089-6097
74. Schuurhuis D.H., Ioan-Facsinay A., Nagelkerken B., van Schip J.J., Sedlik C., Melief C.J.M., Verbeek J.S., and Ossendorp F. Antigen-antibody immune complexes empower dendritic cells to efficiently prime ppecific CD8+ CTL responses in vivo. J. Immunol. 168 (2002) 2240-2246
75. Sebo P., Moukrim Z., Kalhous M., Schaft N., Dadaglio G., Sheshko V., Fayolle C., and Leclerc C. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8+ T-cell epitope. FEMS Immunol. Med. Microbiol. 26 (1999) 167-173
76. Smith D.C., Lord J.M., Roberts L.M., and Johannes L. Glycosphingolipids as toxin receptors. Semin. Cell Dev. Biol. 15 (2004) 397-408
77. Soilleux E.J., Morris L.S., Leslie G., Chehimi J., Luo Q., Levroney E., Trowsdale J., Montaner L.J., Doms R.W., Weissman D., Coleman N., and Lee B. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J. Leukoc. Biol. 71 (2002) 445-457
78. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2 (2002) 185-194
79. Suzue K., and Young R.A. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 156 (1996) 873-879
80. Tacken P.J., de Vries I.J., Gijzen K., Joosten B., Wu D., Rother R.P., Faas S.J., Punt C.J.A., Torensma R., Adema G.J., and Figdor C.G. Effective induction of naive and recall T cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106 (2005) 1278-1285
81. Tillman B.W., Gruijl T.D., Bakker S.A.L., Scheper R.J., Pinedo H.M., Curiel T.J., Gerritsen W.R., and Curiel D.T. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162 (1999) 6378-6383
82. van Broekhoven C.L., Parish C.R., Demangel C., Britton W.J., and Altin J.G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64 (2004) 4357-4365
83. van den Herik-Oudijk I., Capel P.J., van der Bruggen T., and van de Winkel J.G.J. Identification of signaling motifs within human FcγRIIa and FcγRIIb isoforms. Blood 85 (1995) 2202-2211
84. Wallace P.K., Tsang K.Y., Goldstein J., Correale P., Jarry T.M., Schlom J., Guyre P.M., Ernstoff M.S., and Fanger M.W. Exogenous antigen targeted to FcγRI on myeloid cells is presented in association with MHC class I. J. Immunol. Methods 248 (2001) 183-194
85. Wang H., Griffiths M.N., Burton D.R., and Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc. Natl. Acad. Sci. USA 97 (2000) 847-852
86. Wilson N.S., Behrens G.M., Lundie R.J., Smith C.M., Waithman J., Young L., Forehan S.P., Mount A., Steptoe R.J., Shortman K.D., Koning-Ward T.F., Belz G.T., Carbone F.R., Crabb B.S., Heath W.R., and Villadangos J.A. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7 (2006) 165-172
87. Zhang L., Tang Y., Akbulut H., Zelterman D., Linton P.J., and Deisseroth A.B. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc. Natl. Acad. Sci. USA 100 (2003) 15101-15106